Abstract
Since antibiotics use is currently limited due to undesired side effects and the increasing antibiotic resistance of various bacteria strains, there is a pressing need to develop new strategies and methods preventing epidemic outbreaks.
The virulent potency of bacteria relies on a number of different extracellularly secreted factors among which proteases considered as promising, novel drug targets are of special interest. The first evidence that bacterial cysteine, serine and metalloproteinases contributed to the progression of infection was found in the early 70’s. This extracellular proteolytic system allows bacteria to penetrate into tissues, escape detection by the host’s immune mechanisms and grow despite limited access to nutrition. A molecule able to selectively inhibit the activity of bacterial proteases in the spread of infection may lead to designing novel therapeutics. Moreover, due to their mechanism of action, bacterial protease inhibitors can be used to fight antibiotic-resistant strains.
Herein, we undertake a review of various bacterial proteases together with the design and development of their inhibitors (excluding β-lactams) for the last ten years, and introduce the reader to a brief history of the subject.
Keywords: Inhibitors, bacterial serine proteases, potential antibiotics, bacteria, epidemic outbreaks, metalloproteinases.
Current Pharmaceutical Design
Title:The Lord of the Bacteria: The Fellowship of the Leader and Other Serine Protease Inhibitors
Volume: 24 Issue: 37
Author(s): Ewa Burchacka*Marcin Sieńczyk
Affiliation:
- Department of Medicinal Chemistry and Microbiology, Faculty of Chemistry, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, 50-370 Wroclaw,Poland
Keywords: Inhibitors, bacterial serine proteases, potential antibiotics, bacteria, epidemic outbreaks, metalloproteinases.
Abstract: Since antibiotics use is currently limited due to undesired side effects and the increasing antibiotic resistance of various bacteria strains, there is a pressing need to develop new strategies and methods preventing epidemic outbreaks.
The virulent potency of bacteria relies on a number of different extracellularly secreted factors among which proteases considered as promising, novel drug targets are of special interest. The first evidence that bacterial cysteine, serine and metalloproteinases contributed to the progression of infection was found in the early 70’s. This extracellular proteolytic system allows bacteria to penetrate into tissues, escape detection by the host’s immune mechanisms and grow despite limited access to nutrition. A molecule able to selectively inhibit the activity of bacterial proteases in the spread of infection may lead to designing novel therapeutics. Moreover, due to their mechanism of action, bacterial protease inhibitors can be used to fight antibiotic-resistant strains.
Herein, we undertake a review of various bacterial proteases together with the design and development of their inhibitors (excluding β-lactams) for the last ten years, and introduce the reader to a brief history of the subject.
Export Options
About this article
Cite this article as:
Burchacka Ewa *, Sieńczyk Marcin , The Lord of the Bacteria: The Fellowship of the Leader and Other Serine Protease Inhibitors, Current Pharmaceutical Design 2018; 24 (37) . https://dx.doi.org/10.2174/1381612825666181219163922
DOI https://dx.doi.org/10.2174/1381612825666181219163922 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Therapy for Myocardial Repair
Current Cardiology Reviews Cytokine Therapeutics for Asthma: An Appraisal of Current Evidence and Future Prospects
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Nanoscience Graphical Abstracts
Inflammation & Allergy - Drug Targets (Discontinued) The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Repertoire of Gluten Peptides Active in Celiac Disease Patients: Perspectives For Translational Therapeutic Applications
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: Peripheral Proteins as Drug Targets (Guest Editor: Robert V. Stahelin) ]
Current Drug Targets Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry New Actors for the Immunological Mechanisms Involved in the Materno- Fetal Tolerance
Current Women`s Health Reviews FoxO Proteins: Regulation and Molecular Targets in Liver Cancer
Current Medicinal Chemistry Evaluation of Human Hepatocytes Under Prolonged Culture in a Novel Medium for the Maintenance of Hepatic Differentiation: Results with the Model Pro-inflammatory Cytokine Interleukin 6
Drug Metabolism Letters Genetic Vaccination for the Immunotherapy of B-Cell Malignancies
Current Gene Therapy Diagnosis of Invasive Candidiasis: From Gold Standard Methods to Promising Leading-edge Technologies
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells: Potential in Treatment of Neurodegenerative Diseases
Current Stem Cell Research & Therapy Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews Withdrawal Notice: Synergistic Effect of Myricetin and Phenolic Acid Derivatives on the Reversal of Dengue Fever Related Thrombocytopenia and its Pharmacokinetics study in Plasma by using HPLC and UPLC-Q-TOF
Current Drug Metabolism Leukocyte-Endothelial Cell Interactions: A Therapeutic Target to Ameliorate Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Aptamers Overview: Selection, Features and Applications
Current Topics in Medicinal Chemistry Guide of Hypertensive Crisis Pharmacotherapy
Cardiovascular & Hematological Disorders-Drug Targets The Protein Profile of Fibroblasts: The Role of Proteomics
Current Proteomics